ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
The exacerbating effects of stable pulmonary tuberculosis on the deterioration of inflammatory response, coagulation function, and pulmonary function in COPD: A propensity score-matched retrospective study.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbidity of chronic obstructive pulmonary disease and pulmonary tuberculosis: a bibliometric analysis (2011-2025) with narrative review.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) and tuberculosis pose significant public health challenges, particularly in tuberculosis-endemic developing regions where their co-prevalence may exacerbate the disease burden of chronic airflow obstruction. This study aimed to investigate the impact of stable pulmonary tuberculosis on inflammatory status, coagulation function, and pulmonary function in COPD patients during acute exacerbations.We conducted a retrospective analysis of 68 COPD patients with acute exacerbation and stable pulmonary tuberculosis (observation group) admitted between December 2019 and December 2023. Using propensity score matching based on age and gender, we selected 68 COPD patients without stable pulmonary tuberculosis as the control group. Comparative analysis of laboratory tests and pulmonary function parameters revealed that the observation group had significantly elevated levels of erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), lymphocyte count, platelet count (PLT), and D-dimer, along with significantly reduced pulmonary function parameters including forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) and forced expiratory flow between 25 %-75 % of vital capacity (FEF25-FEF75) (all P < 0.05). Correlation analysis demonstrated positive associations between ESR/IL-6 levels and D-dimer, PLT, and fibrin(ogen) degradation product (FDP) levels (P < 0.05).Binary logistic regression analysis of 14 significantly different variables identified IL-6 (OR = 1.056), ESR (OR = 1.022), PLT (OR = 1.005), D-Dimer (OR = 1.002), FEV1/FVC (OR = 0.962), FEF50 (OR = 0.534), and FEF75 (OR = 0.089) as independent factors associated with acute exacerbation in COPD patients with stable pulmonary tuberculosis (all P < 0.05). Our findings indicate that elevated IL-6, ESR, PLT, and D-Dimer levels coupled with decreased FEV1/FVC, FEF50, and FEF75 levels represent distinctive clinical characteristics of these patients.This study demonstrates that COPD patients with stable pulmonary tuberculosis exhibit enhanced inflammatory responses, prothrombotic tendencies, and more severe pulmonary function impairment, providing a scientific basis for developing individualized treatment strategies for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.